You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROR1 positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Breast Tumors Trial in La Jolla (Cirmtuzumab + Paclitaxel)

Active, not recruiting
  • Breast Neoplasms
  • Cirmtuzumab + Paclitaxel
  • La Jolla, California
    University of California, San Diego
May 16, 2022

Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer Trial in Nashville, Houston, San Antonio (NBE-002)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Nashville, Tennessee
  • +2 more
Mar 3, 2022

Advanced/Metastatic Solid Tumors Trial in Frankston, Nedlands, Beijing (EMB07)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Frankston, Victoria, Australia
  • +2 more
Nov 3, 2022

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Advanced Solid Tumor Trial in Beijing (aPD1-MSLN-CAR T Cells)

Not yet recruiting
  • Advanced Solid Tumor
  • αPD1-MSLN-CAR T Cells
  • Beijing, China
    National Cancer Center Cancer Hospital Chinese Academy of Medica
Jul 13, 2023

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16

Recruiting
  • B-cell Chronic Lymphocytic Leukemia
  • +3 more
  • Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
  • +5 more
  • Duarte, California
  • +12 more
Jun 16, 2022

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Dravet Syndrome Trial in Melbourne (ETX101)

Not yet recruiting
  • Dravet Syndrome
  • Melbourne, Australia
    The Royal Children's Hospital
Oct 30, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Body Image, Anti Fat Bias Trial in Bristol (Positive body image TV show, Positive body image music video, Active control TV show

Recruiting
  • Body Image
  • Anti Fat Bias
  • Positive body image TV show
  • +3 more
  • Bristol, United Kingdom
    Centre for Appearance Research, UWE
Nov 21, 2023

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022